Abstract 549P
Background
Interstitial pneumonia (IP) or interstitial lung abnormalities (ILA) is a risk factor for drug-induced interstitial lung disease (D-ILD) in immunotherapy. We usually evaluate interstitial pneumonia by CT findings without histopathological findings. We aimed to evaluate whether histopathological findings of the background lung in surgical specimens is correlated with development of D-ILD by immunotherapy in patients with postoperative recurrence.
Methods
Patients who were treated with immunotherapy or immunochemotherapy for first-line treatment of non-small cell lung cancer for postoperative recurrence from April 2017 to February 2023 were included. We retrospectively compared between characteristics of patients with and without D-ILD, including CT findings and histopathological findings of the background lung in surgical specimens.
Results
Among 32 included patients, we evaluated 27 patients whose surgical specimens were available. The median age was 72 years old, and 20 patients (74.1%) were male. Twelve patients (44.4%) had ILA on CT, and five patients (18.5%) had IP with usual interstitial pneumonia (UIP) pattern (two patients with UIP, one patient with probable UIP, and two patients with indeterminate for UIP) on pathology. Five patients (18.5%) developed D-ILD, including two patients with CTCAE grade 1, two patients with grade 2, and one patient with grade 5. Patients with D-ILD were significantly more likely to have ILA on CT than those without D-ILD (5/5[100%] vs. 7/22[31.8%], p<0.01). Although there was no significant difference, two of the patients with D-ILD had UIP pattern on pathology as compared with three of those without D-ILD (2/5[40%] vs. 3/22[13.6%] p=0.22). Four patients had both ILA on CT and UIP pattern on pathology, and two (50%) of these cases developed D-ILD.
Conclusions
In addition to chest CT findings, histopathological findings of the background lung in surgical specimens may be useful as predictors of D-ILD in immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Tanaka: Financial Interests, Personal, Speaker, Consultant, Advisor: Boehringer Ingelheim GmbH, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo; Financial Interests, Personal, Royalties: Bunkodo Co., Ltd., Gakken Inc. N. Katsurada: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., MSD K.K. T. Nagano: Financial Interests, Personal, Invited Speaker: AstraZeneca K.K. M. Yamamoto: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd. M. Tachihara: Financial Interests, Personal, Invited Speaker: Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd, AstraZeneca K.K, MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co. Ltd., Nippon Boehringer Ingelheim Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo, Janssen Pharmaceutical K.K.; Financial Interests, Institutional, Research Grant: AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening
Presenter: Belinda Lee
Session: Poster Display
Resources:
Abstract
175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma
Presenter: Lan Tu
Session: Poster Display
Resources:
Abstract
176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood
Presenter: HEE SEON Kim
Session: Poster Display
Resources:
Abstract
177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis
Presenter: Pranay Vaghela
Session: Poster Display
Resources:
Abstract
178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data
Presenter: Oh Jeong
Session: Poster Display
Resources:
Abstract
179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients
Presenter: Yuki Ushimaru
Session: Poster Display
Resources:
Abstract
180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer
Presenter: shangguan Zhixin
Session: Poster Display
Resources:
Abstract
181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study
Presenter: Zhen Huang
Session: Poster Display
Resources:
Abstract
182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study
Presenter: Dana Al Zamer
Session: Poster Display
Resources:
Abstract